| abstract |
The embodiment of the present invention relates to a recombinant vector based on a chimpanzee adenovirus vector, an adenovirus, a 2019 novel coronavirus vaccine and a preparation method thereof. The recombinant vector is linearized and packaged into a recombinant adenovirus, and the recombinant adenovirus is pre-existed in the human population Immunity is low and can only be replicated in specific cell lines, so recombinant adenovirus can express foreign genes after infecting animals and humans, but it also has no replication ability in normal cells in animals and humans. It is very useful as a vaccine. Safety. In addition, the recombinant adenovirus has the characteristics of strong ability to express antigen, can induce strong antigen-specific immune response, and is easy to be cultured and produced for large-scale application. More importantly, the 2019 novel coronavirus vaccine containing adenovirus played a better role in protecting mice against pneumonia caused by novel coronavirus infection. |